Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
The acquisition will give Genmab access to ProfoundBio's portfolio of antibody-drug conjugates (ADCs), three of which are in clinical trials. The...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Swiss Biotech Report reporting record turnover
The Swiss Biotech Report 2024 commissioned by the Swiss Biotech Association and co-published with EY on the occasion of the Swiss Biotech Day...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
AZmed closes €15m Series A financing
AZmed said it will use the €15m to boost marketing of its proprietary artificial intelligence (AI) platform Rayvolve worldwide particularly in...